Co-Authors
This is a "connection" page, showing publications co-authored by Oliver Pfaar and Torsten Zuberbier.
Connection Strength
3.280
-
[Handling of allergen immunotherapy in the COVID-19 pandemic: An ARIA-EAACI-AeDA-GPA-DGAKI Position Paper (Pocket-Guide)]. Laryngorhinootologie. 2020 10; 99(10):676-679.
Score: 0.899
-
Technical standards in allergen exposure chambers worldwide - an EAACI Task Force Report. Allergy. 2021 12; 76(12):3589-3612.
Score: 0.245
-
COVID-19 pandemic: Practical considerations on the organization of an allergy clinic-An EAACI/ARIA Position Paper. Allergy. 2021 03; 76(3):648-676.
Score: 0.233
-
Allergen immunotherapy in the current COVID-19 pandemic: A position paper of AeDA, ARIA, EAACI, DGAKI and GPA: Position paper of the German ARIA GroupA in cooperation with the Austrian ARIA GroupB, the Swiss ARIA GroupC, German Society for Applied Allergology (AEDA)D, German Society for Allergology and Clinical Immunology (DGAKI)E, Society for Pediatric Allergology (GPA)F in cooperation with AG Clinical Immunology, Allergology and Environmental Medicine of the DGHNO-KHCG and the European Academy of Allergy and Clinical Immunology (EAACI)H. Allergol Select. 2020; 4:44-52.
Score: 0.221
-
Mobile Technology in Allergic Rhinitis: Evolution in Management or Revolution in Health and Care? J Allergy Clin Immunol Pract. 2019 Nov - Dec; 7(8):2511-2523.
Score: 0.210
-
Next-generation care pathways for allergic rhinitis and asthma multimorbidity: a model for multimorbid non-communicable diseases-Meeting Report (Part 1). J Thorac Dis. 2019 Aug; 11(8):3633-3642.
Score: 0.209
-
Peak nasal inspiratory flow as outcome for provocation studies in allergen exposure chambers: a GA2LEN study. Clin Transl Allergy. 2017; 7:33.
Score: 0.183
-
Allergen exposure chambers: harmonizing current concepts and projecting the needs for the future - an EAACI Position Paper. Allergy. 2017 Jul; 72(7):1035-1042.
Score: 0.179
-
Management of anaphylaxis due to COVID-19 vaccines in the elderly. Allergy. 2021 10; 76(10):2952-2964.
Score: 0.061
-
Differentiation of COVID-19 signs and symptoms from allergic rhinitis and common cold: An ARIA-EAACI-GA2 LEN consensus. Allergy. 2021 08; 76(8):2354-2366.
Score: 0.059
-
Potential Interplay between Nrf2, TRPA1, and TRPV1 in Nutrients for the Control of COVID-19. Int Arch Allergy Immunol. 2021; 182(4):324-338.
Score: 0.058
-
Spices to Control COVID-19 Symptoms: Yes, but Not Only…. Int Arch Allergy Immunol. 2021; 182(6):489-495.
Score: 0.057
-
Correction to: Is diet partly responsible for differences in COVID-19 death rates between and within countries? Clin Transl Allergy. 2020; 10:44.
Score: 0.057
-
Intranasal corticosteroids in allergic rhinitis in COVID-19 infected patients: An ARIA-EAACI statement. Allergy. 2020 10; 75(10):2440-2444.
Score: 0.057
-
ARIA-EAACI statement on asthma and COVID-19 (June 2, 2020). Allergy. 2021 03; 76(3):689-697.
Score: 0.056
-
Use of biologicals in allergic and type-2 inflammatory diseases during the current COVID-19 pandemic: Position paper of Ärzteverband Deutscher Allergologen (AeDA)A, Deutsche Gesellschaft für Allergologie und Klinische Immunologie (DGAKI)B, Gesellschaft für Pädiatrische Allergologie und Umweltmedizin (GPA)C, Österreichische Gesellschaft für Allergologie und Immunologie (ÖGAI)D, Luxemburgische Gesellschaft für Allergologie und Immunologie (LGAI)E, Österreichische Gesellschaft für Pneumologie (ÖGP)F in co-operation with the German, Austrian, and Swiss ARIA groupsG, and the European Academy of Allergy and Clinical Immunology (EAACI)H. Allergol Select. 2020; 4:53-68.
Score: 0.056
-
Handling of allergen immunotherapy in the COVID-19 pandemic: An ARIA-EAACI statement. Allergy. 2020 07; 75(7):1546-1554.
Score: 0.056
-
Is diet partly responsible for differences in COVID-19 death rates between and within countries? Clin Transl Allergy. 2020; 10:16.
Score: 0.055
-
Guidance to 2018 good practice: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma. Clin Transl Allergy. 2019; 9:16.
Score: 0.051
-
MASK 2017: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma multimorbidity using real-world-evidence. Clin Transl Allergy. 2018; 8:45.
Score: 0.049
-
Daily allergic multimorbidity in rhinitis using mobile technology: A novel concept of the MASK study. Allergy. 2018 08; 73(8):1622-1631.
Score: 0.048
-
Treatment of allergic rhinitis using mobile technology with real-world data: The MASK observational pilot study. Allergy. 2018 09; 73(9):1763-1774.
Score: 0.048
-
Transfer of innovation on allergic rhinitis and asthma multimorbidity in the elderly (MACVIA-ARIA) - EIP on AHA Twinning Reference Site (GARD research demonstration project). Allergy. 2018 Jan; 73(1):77-92.
Score: 0.046
-
Erratum to: Scaling up strategies of the chronic respiratory disease programme of the European Innovation Partnership on Active and Healthy Ageing (Action Plan B3: Area 5). Clin Transl Allergy. 2017; 7:5.
Score: 0.044
-
ARIA 2016: Care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle. Clin Transl Allergy. 2016; 6:47.
Score: 0.044